Author:
Han C,Braybrooke J P,Deplanque G,Taylor M,Mackintosh D,Kaur K,Samouri K,Ganesan T S,Harris A L,Talbot D C
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. American Society of Clinical Oncology (1997) Critical role of phase I clinical trials in cancer treatment. J Clin Oncol 15: 853–859
2. Bachelot T, Ray-Coquard I, Catimel G, Ardiet C, Guastalla JP, Dumortier A, Chauvin F, Droz JP, Philip T, Clavel M (2000) Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 11: 151–156
3. Braybrooke JP, Boven E, Bates NP, Ruijter R, Dobbs N, Cheverton PD, Pinedo HM, Talbot DC (2003) Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f) using a weekly 30-minute intra-venous infusion, in patients with advanced solid malignancies. Ann Oncol 14: 913–921
4. Braybrooke JP, Propper DJ, O'Byrne KJ, Koukourakis MI, Patterson AV, Houlbrook S, Love SD, Varcoe S, Taylor M, Ganesan TS, Talbot DC, Harris (2000) Induction of thymidine phosphorylase as a pharmaco-dynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha. Br J Cancer 83: 219–224
5. Chao D, Bahl P, Smith C, Dunbar R, Cerundolo V, Thurner-Schuler B, Austyn JM, Harris AL (2003) A phase I clinical trial of direct intratumoral injection of autologous dendritic cells. Br J Cancer, submitted
Cited by
45 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献